Skip to main content

Clinical Trials Using Enzalutamide

Review the clinical trials studying enzalutamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-49 of 49

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Status: Active
Location: 3 locations
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Status: Active
Location: 3 locations
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Status: Active
Location: 2 locations
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Status: Active
Location: 5 locations
Metastasis-Directed Radiotherapy for the Treatment of Men with Oligometastatic Prostate Cancer, METANOVA Trial
Status: Active
Location: 2 locations
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Status: Active
Location: 2 locations
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Status: Active
Location: 2 locations
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Status: Active
Location: 2 locations
Enzalutamide and Talazoparib with Androgen Deprivation Therapy for the Treatment of Patients with Prostate Cancer that is Metastatic to the Lymph Nodes at Diagnosis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Eflornithine and Testosterone Followed by Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, APEX Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 2 locations
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Status: Active
Location: 2 locations
Cell Therapy (STEAP1 CART) with Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Telmisartan Alone or Combined with Selected Standard of Care Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Status: Active
Location: 3 locations
Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer
Status: Active
Location: 2 locations